ABIONYX Pharma Croissance future

Future contrôle des critères 2/6

Les bénéfices de ABIONYX Pharma devraient diminuer de 23.4% par an tandis que son chiffre d'affaires annuel devrait croître de 40.7% par an. Le BPA devrait croître de en baisse de 13.8% par an.

Informations clés

-23.4%

Taux de croissance des bénéfices

-13.8%

Taux de croissance du BPA

Biotechs croissance des bénéfices	37.1%
Taux de croissance des recettes	40.7%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	15 Nov 2024

Mises à jour récentes de la croissance future

Pas de mise à jour

Recent updates

Prévisions de croissance des bénéfices et des revenus

LSE:0RAG - Estimations futures des analystes et données financières antérieures (EUR Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	12	-7	-7	-7	1
12/31/2025	7	-9	-9	-9	1
12/31/2024	5	-6	-6	-6	1
6/30/2024	5	-3	-3	-3	N/A
3/31/2024	5	-3	-3	-3	N/A
12/31/2023	5	-4	-4	-4	N/A
9/30/2023	5	-4	N/A	N/A	N/A
6/30/2023	5	-4	-2	-2	N/A
3/31/2023	5	-4	-3	-3	N/A
12/31/2022	5	-4	-4	-3	N/A
9/30/2022	4	-5	N/A	N/A	N/A
6/30/2022	3	-6	-6	-6	N/A
3/31/2022	2	-6	-6	-6	N/A
12/31/2021	1	-6	-7	-7	N/A
9/30/2021	0	-5	N/A	N/A	N/A
6/30/2021	0	-4	-6	-5	N/A
3/31/2021	0	-3	-3	-3	N/A
12/31/2020	N/A	-2	-1	-1	N/A
9/30/2020	N/A	-2	-1	-1	N/A
6/30/2020	N/A	-2	0	0	N/A
3/31/2020	N/A	0	-2	-2	N/A
12/31/2019	N/A	2	-4	-4	N/A
9/30/2019	0	1	-5	-5	N/A
6/30/2019	0	0	-6	-6	N/A
3/31/2019	0	-3	-6	-6	N/A
12/31/2018	0	-6	-6	-6	N/A
9/30/2018	0	-7	-6	-6	N/A
6/30/2018	N/A	-8	-7	-7	N/A
3/31/2018	N/A	-6	N/A	-8	N/A
12/31/2017	N/A	-5	N/A	-9	N/A
9/30/2017	N/A	-8	N/A	-11	N/A
6/30/2017	N/A	-11	N/A	-13	N/A
3/31/2017	N/A	-18	N/A	-16	N/A
12/31/2016	N/A	-25	N/A	-19	N/A
9/30/2016	N/A	-25	N/A	-19	N/A
6/30/2016	N/A	-24	N/A	-19	N/A
3/31/2016	N/A	-20	N/A	-16	N/A
12/31/2015	N/A	-17	N/A	-14	N/A
9/30/2015	N/A	-13	N/A	-11	N/A
6/30/2015	N/A	-10	N/A	-8	N/A
3/31/2015	N/A	-8	N/A	-6	N/A
12/31/2014	N/A	-7	N/A	-3	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: 0RAG devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: 0RAG devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: 0RAG devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de 0RAG ( 40.7% par an) devrait croître plus rapidement que le marché UK ( 3.5% par an).

Croissance élevée des revenus: Le chiffre d'affaires de 0RAG ( 40.7% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de 0RAG devrait être élevé dans 3 ans

ABIONYX Pharma Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Recent updates

ABIONYX Pharma RACERS Study Clinical Results in Brain-Fog Selected for Poster Presentation at the American Society of Nephrology (ASN) 2024 Annual Meeting Kidney Week

First half 2024 earnings released

ABIONYX Pharma Completes Pre-IND Meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis

ABIONYX Pharma SA, Annual General Meeting, Jun 27, 2024

ABIONYX Pharma SA to Report Q2, 2024 Results on Aug 22, 2024

Insufficient new directors

Insufficient new directors

New minor risk - Revenue size

Full year 2023 earnings released

ABIONYX Pharma SA to Report Q2, 2024 Results on Sep 26, 2024

Insufficient new directors

ABIONYX Pharma SA Acknowledges the Clinical Results of the Phase 3 Aegis-Ii Study Evaluating the Efficacy and Safety of Csl Behring’S Human-Plasma-Derived Apoa-I, CSL112

ABIONYX Pharma Appoints Rob Scott as Chief Medical Officer and Head of R&D

ABIONYX Pharma Presents Preclinical Results for CER-001 in Brain Fog, At the 1st International Scientific Congress on Brain-Kidney Interaction in Naples on November 23-24, 2023

ABIONYX Pharma Announces New Positive Results in a Uveitis Model for the Strategic Development of the First Class of Biomedicines in Ophthalmology Based on its Recombinant apoA-I

Abionyx Pharma Racers Study Data in Sepsis Presented At the American Society of Nephrology (Asn) 2023 Annual Meeting "Kidney Week"

New minor risk - Share price stability

ABIONYX Pharma RACERS Study in Sepsis Selected for Late-Breaking Clinical Results Poster Presentation at the American Society of Nephrology 2023 Annual Meeting " Kidney Week"

First half 2023 earnings released

New minor risk - Shareholder dilution

ABIONYX Pharma Successfully Manufactures a Second Batch of Recombinant Human ApoA-I CER-001 Using a New, Innovative and Robust Industrial Bioprocess

New major risk - Revenue and earnings growth

ABIONYX Pharma Announces New Compassionate Access Authorization (CAA) for CER-001 in the Rare Disease LCAT Deficiency or Norum Disease in Europe

ABIONYX Pharma Announces New Compassionate Access Authorization (CAA) for CER-001 in the Rare Disease LCAT Deficiency or Norum Disease in Europe

ABIONYX Pharma SA, Annual General Meeting, Jun 28, 2023

ABIONYX Pharma SA to Report Q2, 2023 Results on Aug 17, 2023

ABIONYX Pharma Announces Successful Manufacturing of the First Batch of CER-001 with Recombinant Human ApoA-I Using aNew Innovative and Robust Industrial Bioprocess

Full year 2022 earnings released

ABIONYX Pharma Reports Positive Results from Phase 2A Pilot Clinical Trial

ABIONYX Pharma SA to Report Fiscal Year 2022 Results on Apr 27, 2023

Insufficient new directors

Insufficient new directors

Insufficient new directors

ABIONYX Pharma SA Announces Final Patient Enrollment in Phase 2a Clinical Trial with CER-001, Bio-HDL for the Treatment of Patients with Sepsis at High Risk of Developing Acute Kidney Injury

Insufficient new directors

First half 2022 earnings released

ABIONYX Pharma Reports Positive Interim Results from Phase 2A Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients At High Risk of Developing Acute Kidney Injury

ABIONYX Pharma Receives FDA Orphan Drug Designation (ODD) for CER-001 for the Treatment of LCAT Deficiency Presenting as Kidney Dysfunction and/or Ophthalmologic Disease

ABIONYX Pharma SA to Report First Half, 2022 Results on Sep 29, 2022

ABIONYX Pharma Announces That the French Drug Safety Agency Has Granted a Compassionate Access Authorization for the bio-HDL (CER-001) in COVID-19 Disease

ABIONYX Announces First Patient Enrolled in Phase 2a Clinical Study With CER-001, the Bio-HDL for the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury

Investor sentiment improved over the past week

ABIONYX Announces Positive Clinical Results From CER-001 in an Ultrarare Kidney Disease Published in the Annals of Internal Medicine

ABIONYX Pharma SA to Report First Half, 2021 Results on Sep 09, 2021

ABIONYX Pharma SA Initiates a Phase 2a Clinical Trial With CER-001 in Septic Patients at High Risk of Developing Acute Kidney Injury

ABIONYX Pharma Announces Publication of Pre-Clinical Data in the Journal Metabolism Demonstrating CER-001 Improves Lipid Profile and Kidney Function for an Ultra-Rare Kidney Disease

ABIONYX Pharma Announces the Observation of Positive Therapeutic Signals in Temporary Authorizations for Use (ATUn) in France and Italy for an Ultra-Rare Kidney Disease

ABIONYX Pharma SA announced that it expects to receive €1.859997 million in funding from Domundi SC and other investors

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance